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Background: The increased use of human biological material for cell-based research and clinical interventions
poses risks to the privacy of patients and donors, including the possibility of re-identification of individuals from
anonymized cell lines and associated genetic data. These risks will increase as technologies and databases used for
re-identification become affordable and more sophisticated. Policies that require ongoing linkage of cell lines to donors’
clinical information for research and regulatory purposes, and existing practices that limit research participants’ ability
to control what is done with their genetic data, amplify the privacy concerns.
Discussion: To date, the privacy issues associated with cell-based research and interventions have not received much
attention in the academic and policymaking contexts. This paper, arising out of a multi-disciplinary workshop, aims to
rectify this by outlining the issues, proposing novel governance strategies and policy recommendations, and identifying
areas where further evidence is required to make sound policy decisions. The authors of this paper take the position
that existing rules and norms can be reasonably extended to address privacy risks in this context without compromising
emerging developments in the research environment, and that exceptions from such rules should be justified using a
case-by-case approach. In developing new policies, the broader framework of regulations governing cell-based research
and related areas must be taken into account, as well as the views of impacted groups, including scientists, research
participants and the general public.
Summary: This paper outlines deliberations at a policy development workshop focusing on privacy challenges
associated with cell-based research and interventions. The paper provides an overview of these challenges,
followed by a discussion of key themes and recommendations that emerged from discussions at the workshop. The
paper concludes that privacy risks associated with cell-based research and interventions should be addressed through
evidence-based policy reforms that account for both well-established legal and ethical norms and current knowledge
about actual or anticipated harms. The authors also call for research studies that identify and address gaps in
understanding of privacy risks.* Correspondence: uogbogu@ualberta.ca
1Faculties of Law and Pharmacy & Pharmaceutical Sciences, University of
Alberta, 116 Street and 85 Avenue, Edmonton T6G 2R3, Canada
2Health Law Institute, Faculty of Law, University of Alberta, 116 Street and 85
Avenue, Edmonton T6G 2R3, Canada
Full list of author information is available at the end of the article
© 2014 Ogbogu et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Ogbogu et al. BMC Medical Ethics 2014, 15:7 Page 2 of 7
http://www.biomedcentral.com/1472-6939/15/7Background
Uses of human biological materials for cell-based research
and interventions have re-ignited persistent worries re-
garding the protection of genetic privacy in an era where
openness, sharing, and access to affordable and accessible
genetic testing technologies are increasingly commonplace.
While the privacy challenges associated with cell-based re-
search and interventions are by no means unique, they
have become more evident in light of the considerable
public interest and scientific excitement surrounding
ground-breaking recent discoveries in the field, such as
induced pluripotent stem cells (iPSCs) [1,2], somatic-cell
nuclear transfer (SCNT) derived human embryonic stem
cells (hESCs) [3] and triploid human embryonic stem cells
(hESCs) [4]. In this article, we examine and offer recom-
mendations for addressing these privacy challenges through
the lens of cell-based research and interventions, while
recognizing that the derivation and sharing of stem cell
lines are a critical part of good scientific practice [5], and
that the privacy challenges discussed here are engaged
equally (or perhaps more markedly) in other contexts,
such as in relation to genetic research and biobank datasets.
Indeed, our discussion of the stem cell context will ne-
cessarily canvass and draw upon the academic literature
on privacy issues facing genetic research.
In the context of cell-based research and interventions, a
specific concern relates to potential privacy risks surround-
ing research uses of iPSCs. There is emerging scientific
consensus that these stem cell lines retain substantial
genetic characteristics of the parent/donor somatic cell
or tissue [6,7]. Accordingly, an individual could be re-
identified from anonymized or anonymous genetic data
derived from such cell lines. Moreover, in most cases, cell
lines will be linked to the donor’s clinical information for
both research and regulatory purposes [8]. Insecure hand-
ling or misuse of these lines and associated clinical informa-
tion could also result in disclosure of personal information
to unauthorized parties. The highly collaborative nature of
cell therapy research and the transnational movement of
stem cell lines and associated health information reinforce
privacy concerns, and have generated calls for policy inter-
vention [9-11]. Privacy concerns, among other ethical and
legal issues associated with cross-jurisdictional transfer of
stem cell lines, also suggest a need for harmonization of
policy responses across jurisdictions [12-15]. Indeed, it has
been observed that conceptual and logistical impediments
to international sharing of biological resources can be
overcome by harmonizing privacy standards through a
continuing process that fosters the interplay of different
national viewpoints [16].
Furthermore, recent studies have demonstrated the
possibility of re-identifying research participants from
anonymized genetic data [17-19] by linking such data
with freely available information in the public domain,such as familial database records, and demographic infor-
mation obtained through Internet searches [10,18,20-22].
However, these re-identification studies currently require
highly sophisticated technical ability and technological
resources, and involve complex and specialized processes,
with very limited success rates [23]. Also, institutional data
use policies may preclude or impose stringent conditions
on re-identification of research participants from anon-
ymized genetic data or other health information. While it
is possible that re-identification could become easier or
more successful with advances in data linkage technologies,
and proliferation of reference databases (including geneal-
ogy websites, genome-phenome data banks, and linked
electronic medical records) [18,22,24,25], the potential risks
of re-identification are presently neither manifest nor
pressing in magnitude or feasibility [26]. That said, the
potential for re-identification has generated significant
policy and media attention and scrutiny [27-34].
It has been suggested that re-identification may cause
a variety of harms, including harms to donors’ privacy
interests [9,10], the possibility of genetic discrimination
in the context of employment, health care, and life and
medical insurance [35-37], and inappropriate disclosure of
stigmatizing, embarrassing or incriminating genetic infor-
mation [10,35,38]. Also, unauthorized re-identification of
anonymous research participants could undermine public
trust in genetic research and result in public reluctance to
donate biological material for genomics research [39,40].
However, there is presently little evidence to support fears
that these harms will materialize [21,41,42]. Genetic
discrimination in insurance, for example, is uncommon
because the predictive ability of genetic testing is limited,
and most of the information that would arise is already
disclosed through evaluation of family and medical history
[36,42-44].
The foregoing privacy concerns are made more sensitive
by emerging practices that challenge well-established legal
and ethical norms. For instance, consent models, such
as broad consent—which enable donors to consent to
prospective, as-yet-unknown research uses of their donated
materials—are increasingly common in genomics and re-
lated research contexts [45-47]. Likewise, an increasing
number of policy instruments limit the right to withdraw
consent to the use of donated biological materials to a
time before the materials are used for research or a stem
cell line is created [45,48-53]. These practices remain con-
troversial and have generated significant discussion in the
academic community [52-56]. In many jurisdictions, in-
cluding Canada, Australia, the U.S. and the E.U., voluntary
informed consent to identified or specific research studies
is required by applicable policies [57-62]. However, re-
search ethics committees (RECs) can approve studies that
depart from this rule, on a case-by-case basis, but only if
there is minimal risk to participants and the failure to
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or if it would be impossible or impractical to carry out the
research without prior consent from participants [57-59].
Given the significant public interest in cell-based re-
search and interventions, privacy is likely to be a hot area
of policy debate. However, to date, there have been few,
if any, attempts to examine the privacy issues arising in
this context, or to formulate proactive evidence-based
policy guidance to address associated risks. To this end,
and under the auspices of the Office of the Privacy Com-
missioner of Canada Contributions Program, we convened
a workshop to facilitate focused scholarly and policy reflec-
tion and analysis on the privacy risks and issues associated
with cell-based research and interventions. Workshop par-
ticipants consisted of the authors of this paper, and repre-
sent a multi-institutional, multidisciplinary group of legal
scholars, bioethicists, privacy experts, data security experts,
bioinformaticians, stem cell scientists, and trainees in all
these areas. Using a workshop format we have successfully
employed in the past to generate debate and consensus on
policy recommendations [8,63,64], participants presented
on and discussed the following topics: cell-based research
and interventions, current governance regimes and associ-
ated challenges, data security and re-identification studies,
privacy and open access, and consent requirements.
Following the presentations, recommendations formu-
lated by the workshop conveners (Ogbogu, Caulfield and
Burningham) were presented for deliberation and revision.
In the next section, we outline key themes and specific
policy recommendations that emerged from the discus-
sions at the workshop.
Discussion
Theme 1: Re-identification risk is a moving target
Recent research studies have demonstrated the possibility
of successful re-identification of de-identified genetic data
[18,19]. While these studies raise serious questions about
whether de-identification-based privacy guarantees are
adequate to protect research participants against unlawful
use and disclosure of their genetic information, it should
be borne in mind that re-identification attacks are presently
technologically rigorous and expensive, have limited suc-
cess rates, and require specialized equipment and access
to other health data. Re-identification attacks therefore do
not currently raise a level of risk that should be met with
restrictive policies, such as restrictions on open access and
on sharing of genetic research data. Open access policies
should be combined with acceptable use or data use agree-
ments that prohibit re-identification and/or misuse.
The risk of re-identification may increase as technology
improves and/or publicly accessible databases containing
genetic information linkable to identifiable individuals
become more widespread. Policies designed to prevent
unauthorized re-identification should be based on evidenceof actual or anticipated harm, and incorporate processes for
ongoing evaluation of anticipated risk or harm.
Theme 2: Informed consent: “The devil is in the defaults”a
As previously stated, many jurisdictions require researchers
to inform research participants about and obtain their con-
sent to specific research uses of their biological materials
and associated genetic or other health information. This
requirement is typically subject to limited exceptions and
must be complied with prior to commencement of re-
search. Participants must also be made aware of any legally
or ethically sanctioned limits to exercising meaningful
control over their personal health or genetic information
once the research has commenced.
To ensure “a consistent floor of privacy protections” [34],
p. 5, these policies should be maintained as the default in
relation to uses and disclosure of genetic information and
associated health data. Departure from the default rules
may be warranted, but only where the public interest in the
departure clearly outweighs a corresponding public interest
in protecting and preserving individual privacy and auton-
omy. The rationale for setting aside the default rules must
be clearly and specifically demonstrated, and balanced
against actual evidence of consequent benefits and risks.
This approach is necessarily case-specific, and should be
implemented by a body or institution that is familiar with,
or structured to obtain and incorporate into its deliberative
and decision-making process, multiple perspectives on the
research context, associated privacy challenges, participant
preferences, and the risks and benefits of proposed excep-
tions. While it remains an open question whether or not
RECs can fulfill these roles within the scope of their
present mandates [65], an emerging alternative is the
establishment of data access committees that are charged
with the responsibility of overseeing requests or applica-
tions for research use and disclosure of personal health
data, and with monitoring and responding to privacy chal-
lenges resulting from innovations in health research [26,65].
Theme 3: Beyond re-identification risk and consent:
grounding the default in a “big picture” view of policy
development and analysis
There is a need to move scholarly reflection beyond
discussion of re-identification risks and consent issues
surrounding research involving human biological materials.
To encourage a shift in focus, researchers should prioritize
two other relevant areas: the broader framework of policies
and regulations applicable to privacy issues in this context
(such as the impact of access to information law on partici-
pant rights and researcher responsibilities), and studies of
affected groups’ views, such as the views of research partici-
pants, the public, and researchers working in this area.
Some work has been done in both areas, including studies
of public and stakeholder opinions [66-68] and a recent
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for participants’ rights of continued access to and control
over genetic and other health information [69]. However,
de-identification is still an important tool in the privacy
“tool-box”. Even though de-identification of cell lines may
not guarantee privacy, it is one tool to employ in the
construction of a privacy framework and will work in
conjunction with other approaches, such as education
and strengthening of governance mechanisms.
In accordance with this “big picture” approach to policy
development, default rules should be broadly based on
existing policy rules and norms, including privacy and
access to information laws, research ethics guidelines,
government reports and white papers, and non-binding
policy statements issued by influential scientific or research
ethics organizations [34,70-80]. Gaps and warranted excep-
tions should be addressed through governance mechanisms
designed to balance competing public interests that arise in
this research context. To facilitate cross-border research
collaborations, national policies should be designed to
allow for harmonization with other jurisdictions.
Lastly, affected groups’ perspectives must be taken into
account in designing policy, including the views of scien-
tists, clinicians, institutional managers and research partic-
ipants. Research on missing or incomplete perspectives
should be encouraged and prioritized. Specifically, these
groups should be included in policy deliberations and in
the actual policy-making process, in addition to more
traditional “top down” approaches to public consultation
such as public opinion surveys, focus groups and public
commentary.
Recommendation #1: Changes to existing policies
Existing legal and ethical policies (including privacy and
access to information laws and research ethics policies)
should be extended to cover research involving human
biological material that contains identifiable genetic infor-
mation about a research participant. No special rules or
exceptions need apply. Specifically:
i. research participants must be informed of known
risks of re-identification of de-identified genetic data
at the time of donation and consent;
ii. researchers and research institutions should
inform research participants about new risks of
re-identification as they emerge;
iii. researchers and institutions seeking to use or share
human biological material and/or de-identified genetic
data must have policies and processes in place to
monitor and respond to re-identification risks, including
but not limited to controlled access mechanisms;b
iv. legal definitions of “personal information”, “personal
health information” and similar terms should be
expanded to include “human biological material”;v. the term “information custodian” and other similar
terms in privacy and access to information
legislation should be defined to include “persons or
institutions that collect, use, share or disclose
human biological material or genetic information
derived from such samples”;
vi. institutional sharing policies should address privacy
protections for associated clinical health information
collected with human biological material;
vii. policymakers should seek to harmonize policies
across jurisdictions, and to coordinate monitoring
and enforcement processes;
viii. institutions should work out inter-institutional
arrangements to deal with privacy issues either
through delegated or centralized review; and
ix. privacy regulators should establish mechanisms to
monitor technological developments and review and
update best practices in relation to privacy risks
attending to research uses of human biological
materials.
Recommendation #2: Changes to governance mechanisms
The role of RECs in privacy governance in the context of
cell-based research should be clarified. At the moment,
some hurdles may stand in the way of effective oversight,
including the fact that RECs may lack experience in
privacy matters or may exchange rigorous ethics review
for bureaucratic box checking [65,81,82]. Accordingly,
legislation and relevant policies should set out dedicated
governance frameworks to monitor and respond to privacy
challenges in the context of cell-based research. Options to
consider include:
i. revising membership requirements to include
mandatory representation by a privacy expert or IT
security specialist; or
ii. establishing an independent “data access committee”
to review research protocols that raise significant
privacy concerns (perhaps on a referral basis from
RECs) and to provide general guidance in response
to anticipated or existing privacy challenges.
Summary
Addressing privacy challenges and issues facing cell-based
research and interventions requires collaborative reflection
among and response from multiple interested parties,
including scientists, privacy experts, bioethicists, legal
scholars and policymakers. This paper outlines the first
attempt at such an endeavour, and provides a summary
of key themes and recommendations to facilitate and
guide both future discussions and policymaking activities
in this context. While the issues canvassed in the paper,
chiefly the privacy risks surrounding ongoing linkage of
stem cell lines to research participants’ genetic and clinical
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are not necessarily unique. They must therefore be met
with measured evidence-based policy reforms that account
for both well-established legal and ethical norms and
current knowledge about actual or anticipated harms.
Research on privacy issues in this context should focus
on gaps in knowledge, such as canvassing the views of
persons or groups whose interests are most likely to be
affected. Lastly, policy development in this context must
be necessarily proactive and aimed primarily at maintain-
ing public trust in and support for cell-based research and
interventions.
Endnotes
aThis phrase is borrowed from Ian Kerr’s presentation
at the workshop, and is referenced in his earlier editorial
discussing Facebook and privacy [83].
bIn controlled-access agreements, one party agrees to
provide the other with access to specific data or material
on certain conditions relating to security practices or
confidentiality [84].
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